Hearts were perfused with DCC antibody (1 μg/ml), ERK1/2 inhibitor U0126 (50 μmol/L) or L-NAME (100 μmol/L) for 30 min prior to 45 min netrin-1 perfusion. Ischemia/reperfusion injury was consistently produced by subjecting the hearts to 20 min of ischemia, followed by reperfusion for 60 min (with or without netrin-1). Sections of hearts were stained with 2,3,5-TTC and infarct area calculated as % of risk area. (A) Representative TTC stainings of control hearts, and hearts receiving netrin-1, DCC-antibody/netrin-1, U0126/netrin-1 and L-NAME/netrin-1; (B) Infarct size shown in quantitative grouped data of A (Means±SEM, n=5), *p<0.001 vs. control; **p<0.05 vs netrin-1; (C) Creatine kinase (CK) release was measured by collecting effluent during the entire 60 min of reperfusion from control hearts, and hearts receiving netrin-1, DCC-antibody/netrin-1, U0126/netrin-1 and L-NAME/netrin-1 (Means±SEM, n=3). *p<0.05 vs. control; **p<0.05 vs netrin-1; (D) Representative ESR spectra of NO• production of control hearts, and hearts receiving netrin-1, DCC-antibody/netrin-1, U0126/netrin-1 and L-NAME/netrin-1; (E) Grouped data of NO• production of D (Means±SEM, n=5). *p<0.001 vs. control, **p<0.05 vs. netrin-1; (F) Representative ESR spectra of NO• production from IR-ed hearts of WT or DCC+/− mice perfused with netrin-1; (G) Grouped data of NO• production of F (Means±SEM, *p<0.05); (H) Representative TTC stainings of netrin-1 perfused, IR-ed hearts from WT or DCC+/− mice; (I) Infarct size shown in quantitative grouped data of H (Means±SEM, n=3), * p<0.05.